# Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

> **NCT03556592** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 40 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab
- **DRUG:** Caffeine
- **DRUG:** Warfarin
- **DRUG:** Omeprazole
- **DRUG:** Metoprolol
- **DRUG:** Midazolam Hydrochloride

## Key facts

- **NCT ID:** NCT03556592
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-13
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-06-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03556592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03556592, "Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03556592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*